Leukemia, Myeloid, Acute: all 3,035 studies
Page 20 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic MalignanciesCompletedNCT04052126Not applicable
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyActive, not recruitingNCT04027309Phase 3
- Medium Dose of Cytarabine and MitoxantroneStatus unknownNCT04024241
- FT516 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04023071Phase 1
- PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04022785Phase 1
- RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic SyndromeTerminatedNCT04021368Phase 1
- A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML PatientsStatus unknownNCT04015024Phase 2
- Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.Status unknownNCT04014881Phase 1
- Collect and Assess Tissue Samples From Subjects With Hematologic MalignancyCompletedNCT04014764
- ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaWithdrawnNCT04013880Phase 1/2
- Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesActive, not recruitingNCT04013685Phase 1
- Multiple CAR-T Cell Therapy Targeting AMLTerminatedNCT04010877Phase 1/2
- Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid LeukaemiaStatus unknownNCT04008381Phase 1
- AML Expressive WritingTerminatedNCT04006496Not applicable
- A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)Active, not recruitingNCT03987958
- CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03985007Phase 2
- Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03983824Phase 1
- Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03971799Phase 1/2
- Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractorySuspendedNCT03969446Phase 1
- Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic TransplantCompletedNCT03961919Phase 2
- Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute LeukemiaCompletedNCT03957915Early Phase 1
- INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTSStatus unknownNCT03955848Not applicable
- Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell TransplantationTerminatedNCT03951961Phase 2
- HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT03940352Phase 1
- ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell TransplantCompletedNCT03932643Phase 1
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSActive, not recruitingNCT03927261Phase 1
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedNCT03926624Phase 3
- MIF Involvement in AMLActive, not recruitingNCT03918655
- A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT03915379Phase 1
- Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AMLStatus unknownNCT03913312Phase 1/2
- CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT03904251Phase 1
- Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)CompletedNCT03904134Not applicable
- Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AMLWithdrawnNCT03904069Phase 1
- Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75CompletedNCT03902665Phase 2
- Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaCompletedNCT03900949Phase 1
- Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse GeneticsActive, not recruitingNCT03897127Phase 3
- SRSF2 Gene Mutation in Patients With t-MDS/AMLCompletedNCT03894852
- Gamma Delta T Cells in AMLStatus unknownNCT03885076
- Investigation of the Gut Microbiota in Patients With Acute Myeloid LeukemiaCompletedNCT03881826Not applicable
- Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene MutationWithdrawnNCT03881735Phase 2
- CPX-351+GO in Subjects 55 Years Old, or Older, With AMLTerminatedNCT03878927Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
- Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03848754Phase 1
- A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AMLStatus unknownNCT03846362Phase 3
- Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid LeukemiaActive, not recruitingNCT03844815Phase 1
- An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialActive, not recruitingNCT03844048Phase 3
- Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT03843528Phase 1
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyActive, not recruitingNCT03839771Phase 3
- The Effects of AMPC in the Treatments of Refractory or Relapsed AMLStatus unknownNCT03825146Phase 1
- Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult PatientsCompletedNCT03823352Phase 2
- Bisantrene for Relapsed /Refractory AMLCompletedNCT03820908Phase 2
- TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsActive, not recruitingNCT03816319Phase 1
- Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1
- Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid LeukemiaTerminatedNCT03806192Not applicable
- A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesTerminatedNCT03797261Phase 1
- Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of HepatotoxicityStatus unknownNCT03796533Not applicable
- Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic LeukemiaStatus unknownNCT03796390Phase 1
- Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodActive, not recruitingNCT03793478Phase 1/2
- Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)CompletedNCT03790072Phase 1
- Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid LeukemiaActive, not recruitingNCT03789981
- A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeCompletedNCT03787498Phase 1
- MRD-guided Treatment in NPM1mut AML PatientsTerminatedNCT03769532Phase 2
- Lentivirally Redirected CD123 Autologous T Cells in AMLTerminatedNCT03766126Phase 1
- Dexamethasone in Refractory or First Relapsed Acute Myeloid LeukemiaTerminatedNCT03765541Phase 3
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute LeukemiasTerminatedNCT03761069Phase 1
- Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03760523Phase 1
- HDM201 Added to CT in R/R or Newly Diagnosed AMLWithdrawnNCT03760445Phase 1/2
- Cardiovascular Function in Acute LeukemiaCompletedNCT03760237
- Long-term Outcomes for Acute Myeloid Leukemia PatientsStatus unknownNCT03755856
- Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic LeukemiaTerminatedNCT03755154Phase 1
- TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid LeukemiaWithdrawnNCT03752138Phase 1
- Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related FatigueActive, not recruitingNCT03747757Phase 2
- Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive QuizartinibNo longer availableNCT03746912
- Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03745352Phase 2
- IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic SyndromeActive, not recruitingNCT03744390Phase 2
- Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
- Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive ChemotherapyCompletedNCT03728699
- Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationSuspendedNCT03728335Phase 2
- Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT03723681Phase 1
- Expanded Access for CC-486Approved for marketingNCT03723135
- A Study of Perpetrator Drug Interactions of Enasidenib in AML PatientsCompletedNCT03720366Phase 1
- Haplo HCT vs Haplo-cord HCT for Patients With AMLCompletedNCT03719534Phase 3
- Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AMLCompletedNCT03719183
- Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCTStatus unknownNCT03715621
- Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AMLActive, not recruitingNCT03709758Phase 1
- Actinium-225-Lintuzumab in Patients With Acute Myeloid LeukemiaWithdrawnNCT03705858Phase 1
- Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AMLStatus unknownNCT03701217Phase 2/3
- Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)WithdrawnNCT03699384Phase 1/2
- Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid LeukaemiaActive, not recruitingNCT03697707Phase 2
- A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AMLTerminatedNCT03690154Phase 1
- Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML PatientsCompletedNCT03690115Phase 2
- Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML PatientsActive, not recruitingNCT03679650Phase 1
- Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.CompletedNCT03672695Phase 1
- Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedNCT03672539Phase 2
- The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AMLStatus unknownNCT03665480Phase 2/3
- Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLCompletedNCT03661515Phase 1
- Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03659084
- Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AMLStatus unknownNCT03642236Phase 2/3
- A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03625505Phase 1